Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
Cibil Report
Get cibil report
My Account
Log In
Log into your account
Offers
Check out pre-approved offers now!
Languages
Chosen Language: English
Do Not Call
Do not call
En
Marksans Pharma Ltd. Share Price
N/A
1D
1M
3M
6M
1Y
5Y
Day's Range
Low
₹306.45
High
₹312.50
Price Summary
| Previous Close | ₹309.40 |
|---|---|
| Day's Range | ₹306.45 - ₹312.50 |
| Open | ₹312.50 |
| 52 Week Range | ₹155.00 - ₹350.95 |
| Volume | 2,18,362 |
| Market Cap | ₹0.01 |
| Previous Close | ₹308.20 |
|---|---|
| Day's Range | ₹306.45 - ₹312.55 |
| Open | ₹312.55 |
| 52 Week Range | ₹156.00 - ₹350.75 |
| Volume | 13,393 |
| Market Cap | ₹0.01 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 675.61 |
|---|---|
| Market Cap (₹ in Mn) | 0.01 |
| Dividend Yield(%) | 0.29 |
| Price/Earning (TTM) | 25.39 |
| TTM EPS (₹) | 12.35 |
| P/E Ratio | 17.04 |
| Book Value(₹) | 4.27 |
| PAT Margin (%) | 13.83 |
| Face Value (₹) | 1.00 |
| ROCE(%) | 21.10 |
| Trade Value ( ₹ in Lacs) | 41.28 |
|---|---|
| Market Cap (₹ in Mn) | 0.01 |
| Dividend Yield(%) | 0.29 |
| Price/Earning (TTM) | 25.39 |
| TTM EPS (₹) | 12.35 |
| P/E Ratio | 17.04 |
| Book Value(₹) | 4.27 |
| PAT Margin (%) | 13.83 |
| Face Value (₹) | 1.00 |
| ROCE(%) | 21.10 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 7204.09 | 26228.45 |
| Expenses | N/A | N/A |
| PBT | 1333.34 | 5039.67 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 991.39 | 3826.19 |
About Marksans Pharma Ltd.
| Founded | 1992 |
|---|---|
| Managing Director | Mark Saldanha |
| NSE Symbol | MARKSANS |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,37,962.61 | 1,839.00 | 1,583.70 - 1,583.70 |
| Divi's Laboratories Ltd. | 2,69,450.61 | 10,143.80 | 5,647.50 - 5,647.50 |
| Torrent Pharmaceuticals Ltd. | 1,79,455.65 | 4,769.20 | 3,532.60 - 3,532.60 |
| Laurus Labs Ltd. | 1,26,703.22 | 2,315.45 | 917.95 - 917.95 |
| Lenskart Solutions Ltd. | 1,24,984.87 | 723.40 | 0.00 - 0.00 |
| Apollo Hospitals Enterprise Ltd. | 1,20,190.31 | 8,447.50 | 6,696.50 - 6,696.50 |
| Zydus Lifesciences Ltd. | 1,19,341.36 | 1,193.95 | 835.50 - 835.50 |
| Dr. Reddy's Laboratories Ltd. | 1,13,663.75 | 1,361.75 | 1,101.00 - 1,101.00 |
| Cipla Ltd. | 1,13,245.71 | 1,397.30 | 1,165.70 - 1,165.70 |
| Mankind Pharma Ltd. | 1,03,880.84 | 2,511.00 | 1,909.70 - 1,909.70 |
No Records Found
Latest News
Sep
7
2026
Posted on Sep 7th 2026
Marksans Pharma informs about press release
Marksans Pharma has informed that it enclosed copies of newspaper advertisement relating to intimation to the shareholders of the Company regarding transfer of unclaimed dividend and equity shares of the Company to Investor Education and Protection Fund (IEPF) published in Business Standard (English) and Lakshadeep (Marathi) newspapers. The above information is also available on the website of the Company at www.marksanspharma.com.
The above information is a part of company’s filings submitted to BSE.
Read More
Aug
12
2026
Posted on Aug 12th 2026
Marksans Pharma informs about outcome of board meeting
Pursuant to Regulation 33 and Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) and other regulations, if applicable, Marksans Pharma has enclosed the Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter ended June 30, 2026 approved by the Board of Directors of the Company at its Meeting held today. i.e. August 12, 2026 along with Limited Review Reports therein. Pursuant to Regulation 33 of the Listing Regulations as amended, they declared that MSKA & Associates LLP, Chartered Accountants, the Statutory Auditors of the Company have submitted the Limited Review Reports for Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter ended June 30, 2026 with an unmodified opinion. The aforementioned information is also available on the website of the Company at http://www.marksanspharma.com/quarterly-results.html The meeting commenced at 10:50 am and concluded at 12:10 pm.
The above information is a part of company's filings submitted to BSE.
Read More
Nov
6
2026
Posted on Nov 6th 2026
Ipca Laboratories - Quaterly Results
The Revenue for the quarter ended September 2026 of Rs. 22556.10 millions grew by 16.85 % from Rs. 19303.20 millions.A comparatively good net profit growth of 27.09% to Rs. 3872.90 millions was reported for the quarter ended September 2026 compared to Rs. 3047.40 millions of previous same quarter.Operating Profit saw a handsome growth to 6159.80 millions from 4866.30 millions in the quarter ended September 2026.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202609 | 202509 | % Var | 202609 | 202509 | % Var | 202603 | 202503 | % Var | |
| Sales | 22556.10 | 19303.20 | 16.85 | 43748.50 | 36772.20 | 18.97 | 73367.50 | 66779.20 | 9.87 |
| Other Income | 189.20 | 219.20 | -13.69 | 363.40 | 469.40 | -22.58 | 946.40 | 712.90 | 32.75 |
| PBIDT | 6159.80 | 4866.30 | 26.58 | 12110.40 | 9185.70 | 31.84 | 18749.30 | 15963.20 | 17.45 |
| Interest | 46.80 | 114.60 | -59.16 | 97.20 | 235.20 | -58.67 | 435.10 | 630.40 | -30.98 |
| PBDT | 6113.00 | 4751.70 | 28.65 | 12013.20 | 8950.50 | 34.22 | 18010.00 | 12517.40 | 43.88 |
| Depreciation | 775.90 | 668.60 | 16.05 | 1522.00 | 1299.90 | 17.09 | 2688.70 | 2519.70 | 6.71 |
| PBT | 5337.10 | 4083.10 | 30.71 | 10491.20 | 7650.60 | 37.13 | 15321.30 | 9997.70 | 53.25 |
| TAX | 1464.20 | 1035.70 | 41.37 | 2885.40 | 1982.80 | 45.52 | 3996.10 | 3490.10 | 14.50 |
| Deferred Tax | 50.00 | -9.50 | -626.32 | 170.00 | 11.00 | 1445.45 | -25.10 | 81.10 | -130.95 |
| PAT | 3872.90 | 3047.40 | 27.09 | 7605.80 | 5667.80 | 34.19 | 11325.20 | 6507.60 | 74.03 |
| Equity | 253.70 | 253.70 | 0.00 | 253.70 | 253.70 | 0.00 | 253.70 | 253.70 | 0.00 |
| PBIDTM(%) | 27.31 | 25.21 | 8.33 | 27.68 | 24.98 | 10.82 | 25.56 | 23.90 | 6.91 |
Read More
Nov
6
2026
Posted on Nov 6th 2026
Mercury Laboratories - Quaterly Results
The revenue for the September 2026 quarter is pegged at Rs. 190.09 millions against Rs. 190.09 millions recorded during the year-ago period.Net profit of the cmpany stood at Rs. 6.73 millions for the quarter ended September 2026 a decline of -59.06% from Rs. 16.44 millions in the same quarter last year.The Operating Profit of the company witnessed a decrease to 18.15 millions from 29.19 millions.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202609 | 202509 | % Var | 202609 | 202509 | % Var | 202603 | 202503 | % Var | |
| Sales | 190.09 | 190.09 | 0.00 | 349.72 | 371.44 | -5.85 | 759.37 | 751.01 | 1.11 |
| Other Income | 3.78 | 7.91 | -52.21 | 4.30 | 9.72 | -55.76 | 19.55 | 10.69 | 82.88 |
| PBIDT | 18.15 | 29.19 | -37.82 | 30.59 | 54.54 | -43.91 | 109.96 | 80.85 | 36.00 |
| Interest | 1.62 | 1.32 | 22.73 | 2.85 | 2.77 | 2.89 | 5.45 | 5.48 | -0.55 |
| PBDT | 16.53 | 27.87 | -40.69 | 27.74 | 51.77 | -46.42 | 100.56 | 75.37 | 33.42 |
| Depreciation | 7.37 | 8.63 | -14.60 | 14.66 | 17.06 | -14.07 | 34.20 | 28.76 | 18.92 |
| PBT | 9.16 | 19.24 | -52.39 | 13.08 | 34.71 | -62.32 | 66.36 | 46.61 | 42.37 |
| TAX | 2.43 | 2.80 | -13.21 | 3.37 | 8.60 | -60.81 | 18.03 | 15.16 | 18.93 |
| Deferred Tax | 0.13 | -2.90 | -104.48 | -0.23 | -1.90 | -87.89 | 1.42 | 1.68 | -15.48 |
| PAT | 6.73 | 16.44 | -59.06 | 9.71 | 26.11 | -62.81 | 48.33 | 31.45 | 53.67 |
| Equity | 12.00 | 12.00 | 0.00 | 12.00 | 12.00 | 0.00 | 12.00 | 12.00 | 0.00 |
| PBIDTM(%) | 9.55 | 15.36 | -37.82 | 8.75 | 14.68 | -40.43 | 14.48 | 10.77 | 34.51 |
Read More
Nov
6
2026
Posted on Nov 6th 2026
Glenmark Pharma. - Quaterly Results
The turnover zoomed to Rs. 24758.20 millions, up 60.91% for the September 2026 quarter as against Rs. 15386.60 millions during the year-ago period.The Total Profit for the quarter ended September 2026 of Rs. 4348.94 millions grew from Rs.-7391.89 millionsOperating profit for the quarter ended September 2026 rose to 7899.93 millions as compared to 1077.58 millions of corresponding quarter ended September 2025.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202609 | 202509 | % Var | 202609 | 202509 | % Var | 202603 | 202503 | % Var | |
| Sales | 24758.20 | 15386.60 | 60.91 | 49108.13 | 39335.88 | 24.84 | 84400.99 | 92264.09 | -8.52 |
| Other Income | 1081.93 | 2857.56 | -62.14 | 2236.04 | 3550.91 | -37.03 | 7720.23 | 3563.66 | 116.64 |
| PBIDT | 7899.93 | 1077.58 | 633.12 | 15186.57 | 9052.52 | 67.76 | 18494.21 | 26005.46 | -28.88 |
| Interest | 309.34 | 233.96 | 32.22 | 541.79 | 388.54 | 39.44 | 787.45 | 487.33 | 61.58 |
| PBDT | 6161.34 | -8474.32 | -172.71 | 15445.53 | -3886.28 | -497.44 | -301.82 | 23726.47 | -101.27 |
| Depreciation | 629.97 | 589.34 | 6.89 | 1253.14 | 1165.73 | 7.50 | 2358.89 | 2186.29 | 7.89 |
| PBT | 5531.37 | -9063.66 | -161.03 | 14192.39 | -5052.01 | -380.93 | -2660.71 | 21540.18 | -112.35 |
| TAX | 1182.43 | -1671.77 | -170.73 | 2487.08 | -962.38 | -358.43 | -652.72 | 5436.68 | -112.01 |
| Deferred Tax | 144.96 | -970.05 | -114.94 | 321.20 | -962.38 | -133.38 | -652.72 | 2275.81 | -128.68 |
| PAT | 4348.94 | -7391.89 | -158.83 | 11705.31 | -4089.63 | -386.22 | -2007.99 | 16103.50 | -112.47 |
| Equity | 282.22 | 282.20 | 0.01 | 282.22 | 282.20 | 0.01 | 282.20 | 282.19 | 0.00 |
| PBIDTM(%) | 31.91 | 7.00 | 355.61 | 30.92 | 23.01 | 34.38 | 21.91 | 28.19 | -22.26 |
Read More
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Marksans Pharma Ltd. is ₹309.40 as of 2026-11-06.
The market capitalisation of Marksans Pharma Ltd. is ₹14,215.25 as of 2026-11-05.
The 1-year return of Marksans Pharma Ltd. is 122.61% as of 2026-11-06.
The P/E ratio of Marksans Pharma Ltd. is 17.04 as of 2026-11-06.
The 52-week high and low of Marksans Pharma Ltd. are ₹350.95 and ₹155.00, respectively, as of 2026-11-06.
View More
People Also Ask
Marksans focuses on oral solid dosages for OTC and prescription markets, especially in the US, UK, and Australia, including pain, cough‑cold, and GI products.
Marksans Pharma collaborates with pharmaceutical companies and retail distributors through contract manufacturing and supply of generic and OTC formulations. Its products are distributed through regulated market supply chains and are used across primary-care treatment settings, including retail and institutional channels.
View More
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
Home
Shopping
Loan Offers
My Accounts
Explore
